



The Green Organic Dutchman Holdings Ltd.

Management's Discussion and Analysis

For the three and nine months ended September 30, 2020

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis ("MD&A") reports on the consolidated financial condition and operating results of The Green Organic Dutchman Holdings Ltd. (the "Company" or "TGODH") for the three and nine months ended September 30, 2020 and 2019. The MD&A should be read in conjunction with the Company's unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2020 and September 30, 2019 (the "interim consolidated financial statements") which were prepared in accordance with International Accounting Standards ("IAS") 34, Interim Reporting of the International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board. This MD&A provides information on the operating activities, performance and financial position of the Company and is intended to assist in understanding of the Company's business and key factors underlying its financial results. **All dollar amounts referred to in this MD&A are expressed in thousands of Canadian dollars except where indicated otherwise.**

Additional information relating to the Company can be found on the Company's website at www.tgod.ca or at the Company's SEDAR profile at www.sedar.com.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This MD&A may contain "forward-looking information" within the meaning of Canadian securities legislation ("forward-looking statements"). These forward-looking statements are made as of the date of this MD&A and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities laws. Forward-looking statements relate to future events or future performance and reflect Company management's expectations or beliefs regarding future events.

In some cases, these forward-looking statements can be identified by words or phrases such as "may", "might", "will", "expect", "anticipate", "estimate", "intend", "plan", "indicate", "seek", "believe", "predict" or "likely", or the negative of these terms, or other similar expressions intended to identify forward-looking statements. The Company has based these forward-looking statements on its current expectations and projections about future events and financial trends that it believes might affect its financial condition, results of operations, business strategy and financial needs. Some examples of forward-looking statements include but are not limited to the expected costs, completion dates of the facilities, production capacity, receipt of licences, etc.

Assumptions

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate and are subject to risks and uncertainties. In making the forward-looking statements included in this MD&A, the Company has made various material assumptions, including but not limited to:

- (i) the availability of financing at all or on reasonable terms;
- (ii) the Company's ability to continue as a going concern and successfully execute its plans and intentions, including with respect to the construction and operation of the Company's cultivation facilities and generation of revenues and sales of its organic cannabis products;
- (iii) eventual completion of the construction of the Company's facility in Québec;
- (iv) obtaining necessary regulatory approvals;
- (v) general business and economic conditions, particularly in the Canadian medicinal and adult-use cannabis markets;
- (vi) regulation of the markets in which the Company operates;
- (vii) the Company's ability to attract and retain skilled staff;
- (viii) market competition, including the products and technology offered by the Company's competitors;
- (ix) maintenance of our current good relationships with our suppliers, service providers and other third parties; and
- (x) ability to continue to operate during COVID-19 restrictions and maintaining necessary access and safety protocols.

Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There is no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. We do not undertake to update or revise any forward-looking statements, except as, and to the extent required by, applicable securities laws in Canada.

The Company's forward-looking statements are based on the reasonable beliefs, expectations, and opinions of management as of November 10, 2020, the date of this MD&A.

BUSINESS OVERVIEW

The Company was incorporated under the Canada Business Corporations Act on November 16, 2016. The Company's registered and head office is located at 6205 Airport Rd., Building A – Suite 200, Mississauga, Ontario L4V 1E3. The Company completed its initial public offering on May 2, 2018. The Company's Common Shares trade on the TSX under the symbol "TGOD" and on the OTCQX under the symbol "TGODF".

The Company's wholly-owned subsidiaries, The Green Organic Dutchman Ltd. and Medican Organic Inc., are licensed producers under the Cannabis Act (Canada) and hold licences to produce cannabis plants, cannabis plant seeds, dried cannabis, fresh cannabis, cannabis oils, cannabis topicals, cannabis extracts and edible cannabis and, with respect to The Green Organic Dutchman Ltd. only, to process and sell such cannabis products within Canada to provincially authorized retailers and distributors and federally licensed entities. The Company has built a cannabis cultivation and processing facility in Hamilton, Ontario (the "Hamilton Facility") and has substantially completed its current planned scope of construction on another facility located in Valleyfield, Québec (the "Quebec Facility").

In addition to its Canadian operations, the Company, through its subsidiaries and strategic investments, is pursuing an international growth strategy, including through a hemp cultivation and extraction business based in Poland. The Company has also formed a strategic partnership for the distribution of cannabis and hemp-derived medical products in Mexico and joint ventures in Denmark for developing elite cannabis genetics.

The outbreak of the novel strain of the coronavirus, SARS-COV-2 ("COVID-19"), and its eventual declaration as a pandemic by the World Health Organization ("WHO") on March 11, 2020 has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures have caused material disruption to businesses globally resulting in an economic slowdown. The Company rapidly implemented strategic measures to protect its global workforce from COVID-19 and endeavouring to mitigate any long-term impact of the pandemic on its business.

Since inception, the Company has incurred recurring operating losses, having invested significantly in its cultivation facilities, research and development activities and selling, marketing, general and administrative expenses. The Company has financed its operations through equity and debt financings. The Company expects to continue to incur losses in the short term and will require additional capital and revenues through the sale of its organic cannabis products to fulfill its debt obligations. Please refer to the section on "Liquidity and Capital Resources" below.

RECENT DEVELOPMENTS

Executive Leadership Consolidation

On January 9, 2020, the Company announced changes to streamline its leadership structure. The Company's President, Mr. Csaba Reider and the Company's Vice-President of Sales, Mr. Mike Gibbons departed the organization. Mr. Reider's responsibilities were assumed by the Company's Chief Executive Officer ("CEO"), Mr. Brian Athaide and Mr. Gibbons' responsibilities were assumed by the Company's Vice-President of Medical Sales, Mr. Robert Gora.

On November 10, 2020, Brian Athaide has left his positions as CEO and board director effective immediately. The Company's Chief Financial Officer ("CFO"), Sean Bovingdon has been appointed to the position of Interim CEO. In addition, Michel Gagne, Vice-President of Operations, was appointed Chief Operating Officer ("COO") overseeing the Company's cultivation and processing operations, supply chain and product development. In his new role as COO, he will work closely with the CEO on the Company's overall strategy and execution.

Research Licence

On February 20, 2020, the Company announced that it had secured a research licence from Health Canada. Valid for five years, this licence allows the Company to reduce the cost and accelerate the pace at which it develops new products by reducing reliance on third parties.

Hamilton Facility Processing Licence

On March 30, 2020, the Company announced that it had secured a licence amendment from Health Canada in respect of the support building for cannabis processing at the Hamilton Facility. Valid until August 16, 2022, this amendment permits more space and flexibility for the Company to process cannabis for sale as dried flower, oils or in cannabis 2.0 products.

Financings

On April 13, 2020, the Company executed an amendment (the "Senior Loan Amendment") with the lender of the first lien senior secured credit facility (obtained by the Company on December 24, 2019 as described in note 4) which contained an accordion feature of up to \$15,000 based on the Company meeting certain operational milestones. The Senior Loan Amendment made \$5,000 of the accordion available upon closing an equity financing which was achieved on April 27, 2020. The Company received gross proceeds of the accordion loan of \$5,000 on April 27, 2020. In addition, on April 27, 2020 a total of 1,500,000 warrants of the Company were issued to the lender of the first lien senior secured credit facility which are exercisable at \$0.39 for 36 months from the date the warrants were issued, each into one common share of the Company.

On April 22, 2020, the Company closed a secured revolving credit facility ("Revolver Loan") which provided the Company with gross proceeds of \$10,000 with further funding available of up to an additional \$20,000 secured on eligible trade receivables and inventory. As part of the agreement, a total of 3,000,000 warrants of the Company were issued to this lender exercisable at \$0.39 for 36 months from April 22, 2020, each into one common share of the Company. On May 27, 2020, the Company executed an amendment with the lender of the Revolver Loan which extended the original term by six months to October 1, 2021 and allowed the Company to receive \$3,000 in gross proceeds from the \$20,000 revolving component subject to the same terms of the first \$10,000 previously advanced by this lender. In consideration of this, a total of 500,000 warrants were issued on May 22, 2020 to this lender exercisable at \$0.50 for 48 months from the date of issuance. The Company received this \$3,000 on July 7, 2020.

On April 27, 2020, the Company completed a bought-deal equity financing of 20,536,700 units of the Company at \$0.28 per unit for gross proceeds of \$5,750. Each unit consists of one common share of the Company and one-half share purchase warrant of the Company exercisable at \$0.38 for 36 months with each full warrant being exercisable into one common share of the Company.

On June 12, 2020, the Company completed a bought-deal equity financing of 43,125,000 units of the Company at \$0.40 per unit for gross proceeds of \$17,250 ("June Offering"). Each unit consisted of one common share of the Company and one share purchase warrant of the Company with each share purchase warrant exercisable at \$0.50 into one common share of the Company for 48 months from the closing date of the transaction.

On October 23, 2020, the Company obtained gross equity financing ("October Offering") proceeds of \$12,783 by issuing a total of 53,263,400 units of the Company at a price per Unit of \$0.24. Each Unit of the October Offering was comprised of one common share of the Company and three-quarters of one common share purchase warrant of the Company (each whole common share purchase warrant a "Warrant"). Each Warrant entitled the holder to acquire one common share of the Company for a period of 60 months from closing of the transaction at an exercise price of \$0.30 per Warrant.

Cost Reduction Initiatives and Consolidation of Cultivation at the Hamilton Facility

On March 25, 2020, the Company announced that in response to market conditions, it is adapting operations and aggressively reducing costs, including by postponing the start-up and construction of its Québec Facility in order to centralize cultivation in Canada at its Hamilton Facility. The Company has also undertaken further cost reduction measures including some temporary salary reductions and a freeze on non-essential recruitment and consultancy work.

The Hamilton Facility is complete with the hybrid greenhouse growing space is being utilized for normal growing operations. The processing centre was substantially completed from a construction perspective in March 2020 and Health Canada approval was obtained. Processing began in this building for Q2-2020. The Company expects total production output for the 2020 fiscal year to be approximately 8,000 to 9,000 kgs which is expected to be sufficient to meet the Company's latest sales forecast for fiscal 2020, refer to "Business Objectives and Milestones".

Quebec Facility Licence Amendment

On May 7, 2020, the Company announced that it has received Health Canada's approval for its main hybrid greenhouse at the Quebec Facility. The licence amendment is valid until June 8, 2021 and is subject to customary terms and conditions.

Shoppers Supply Agreement

On May 19, 2020, the Company signed a supply agreement with Medical Cannabis by Shoppers™ ("Shoppers"), a subsidiary of Shoppers Drug Mart Inc., making its certified organic medical cannabis products available via the Shoppers online medical cannabis sales platform.

Expiry of warrants

On May 2, 2020, 15,092,063 warrants of the Company exercisable at \$7 per share expired unexercised.

Sale of Epican Medicinals Limited

On May 25, 2020, the Company sold its interest in Epican Medicinals Limited ("EML") to another shareholder of EML for a nominal amount given its history of operating losses, recent economic developments in Jamaica restricting operations and the Company's strategic decision to no longer pursue opportunities in Jamaica and focus on Canadian operations. Upon completion of the disposition, EML repaid \$258 of a \$707 loan owing by EML as at March 31, 2020 to the Company and issued the Company a promissory note for the balance of \$449.

Entry into Quebec Market

On May 26, 2020, the Company announced that it had launched key products Highly Dutch, a mainstream brand of certified organic cannabis at an accessible price, as well as cannabis-infused teas, in the province of Quebec. Highly Dutch was first made available in Quebec in a 28-gram format, before launching across the rest of Canada in the Fall of 2020.

Launch of Stillwater's Ripple Brands in Canada

On June 15, 2020, the Company announced that it had expanded its exclusive licensing agreement with Colorado-based 5071 Inc. for its Stillwater Brands products ("Stillwater"), would be rolling out the powerful RIPPLE suite of products in Canada, including RIPPLE Gummies and RIPPLE QuickSticks. Leveraging Stillwater's proprietary technology, TGOD launched its first Cannabis 2.0 product at the end of March – TGOD Infuser 10mg THC – which quickly became one of the top selling SKUs within the beverage category across the country. Given the success of this first product, TGOD has decided to expand the series by introducing additional formats. Moving forward, all formats will fall under the well-established RIPPLE brand name.

EU-GMP Certification Update

On July 10, 2020, the Company announced that its Hamilton facility had obtained a European Union Good Manufacturing Practice ("EU-GMP") certificate enabling it to commence exports to Germany. Under this EU-GMP certificate, valid until December 31, 2020, TGOD can commence exporting its premium certified organic products for validation in preparation for commercialization in 2021. The Company anticipates validation will be completed by the end of the year, subsequently enabling export of medical cannabis products for commercial purposes to Europe and other jurisdictions.

Senior Secured Credit Facility

On October 2, 2020, the Company agreed with its senior lender to extend the maturity date for its senior secured credit facility to December 15, 2021 in exchange for payment of a financing fee of \$403; repricing of common share purchase warrants to purchase 7,000,000 Common Shares expiring December 20, 2022 from an exercise price of \$1.00 per share to an exercise price of \$0.30 per share expiring November 2, 2025; and issuance of additional common share purchase warrants to purchase 1,000,000 Common Shares at an exercise price of \$0.30, expiring November 2, 2025.

Revolving Credit Facility

On October 1, 2020, the Company agreed with its lender under its revolving credit facility to extend the maturity date for its revolving credit facility to December 31, 2021 in exchange for common share purchase warrants to purchase 500,000 Common Shares at a price of \$0.30 per share, expiring November 2, 2025.

Update on Quebec Facility; Development of Chocolate-Based Products

On September 16, 2020, the Company provided an update on its Quebec Facility, announcing that it had completed the necessary equipment transfers to transform the Quebec Facility into a production and processing hub for its 2.0 products following challenges with third-party processing. Production at the Quebec Facility of dissolvable powders, premium teas and concentrates

has commenced, as have sales of hash under the Company's Highly Dutch brand. In addition, the Company announced that it has entered into a non-binding letter of intent with a Quebec-based chocolatier for a new line of premium organic cannabis-infused chocolate. The Company expects that infused chocolate will be processed at the Quebec Facility using premium Belgian chocolate, gourmet organic ingredients, and the Company's organically grown cannabis and existing fast-acting cannabis infusing technology.

COVID-19

The Company continues to monitor and adapt to changing market conditions including but not limited to the ongoing impact of the COVID-19 pandemic. See "Risk Factors". The Hamilton Facility and Quebec Facility have each implemented precautionary measures to ensure the safety of the staff and product, including limiting visits to the site to essential personnel only, ensuring proper protocols around sanitation, mask usage and physical distancing and ensuring potentially exposed employees remain in self-quarantine for the appropriate period. However, cultivation is continuing and ongoing and additional licensed space available in the processing centre at the Hamilton Facility allows for better physical distancing among our cultivation and processing employees. The Company received wage subsidies from the Canadian federal government under the Canada Emergency Wage Subsidy ("CEWS") and continues to monitor its eligibility for various government support programs.

OVERALL PERFORMANCE

Business Objectives and Milestones

The focus of the Company's activity is the ramp up of commercial operations and the production and sale of its organically grown cannabis products in order to achieve positive Canadian operating cash flows. Construction of the Hamilton Facility is complete, and currently planned construction of the Quebec Facility is substantially complete, with only \$655 of *additional* capital expenditure (related to electrical work and installation of interior walls and finishings) required to complete planned construction to operate per the recent development's intended use described above. The electrical work is expected to be completed in November 2020 and the installation of interior walls and finishings by April 2021. The Company recently completed development and launch of key products – a mainstream-priced dried organically grown cannabis flower brand, called Highly Dutch, and cannabis-infused teas. The Company has also launched a line of water-soluble cannabis powder, which can be infused into any food or beverage, which is distributed under the Ripple™ brand of products. The Company completed its first shipment of a mix of its products, including Highly Dutch and cannabis-infused teas and Ripple™, to Quebec's provincial distribution board on May 26, 2020. Since that time, the Company has worked to generate purchase orders and cultivate, process and ship its organically grown cannabis products across Canada and has recorded strong sales of the product it has shipped to Quebec.

Since the launch of the Company's key products, sales of the Company's shipped products began strong. However, various factors related to production and processing in August 2020 caused the Company to revise its forecasted timeline for achieving positive Canadian operating cash flows from August 2020 (as forecasted in the Company's short form prospectus dated June 9, 2020) to beginning in the first quarter of 2021 (as forecasted in the Company's short form prospectus dated October 19, 2020). As at the date of this MD&A, the Company continues to target increased revenue and reduced operating costs in moving towards achieving positive Canadian operating cash flows in the foreseeable future.

The delay in achieving positive Canadian operating cash flow is the result of a number of factors. Principally, the Company's revenue ramp and resulting cash flow shifted out due to capacity gaps in production at a third-party processor of Cannabis 2.0 products and operational challenges in the Hamilton Facility. The Company had been outsourcing the processing of its Cannabis 2.0 products to third party contractors. To remedy the issues with Cannabis 2.0 production caused by the third-party reliance, the Company has chosen to bring its production of premium organic teas and Ripple infusers in-house to its Quebec Facility. As a result, the Company incurred approximately \$200,000 of start up costs, in the form of acquiring equipment needed for processing. The transfer of equipment in order to carry out these activities took place in early September. This change along with the initiation of hash and chewables production is expected to help with capacity utilization at the Quebec Facility. By producing the Company's Cannabis 2.0 products in-house, the Company expects to realize a reduction in production costs.

With regards to challenges at the Hamilton Facility, the start-up commissioning and calibrations of the energy center led to inconsistent climate controls in the hybrid greenhouse during the very hot weather in late July and early August, which led to several August harvests not meeting the Company's strict premium flower specifications. As a result, most of the flower from these harvests is now being used for extraction. The Company, with support from its equipment vendors, has since finetuned calibrations to significantly reduce the energy center downtimes resulting in improved climate controls and harvests in September have met the Company's specifications. However, the resulting delays caused lower than expected flower availability and a shifting of the national Highly Dutch expansion from Quebec to the balance of the country into the fourth quarter of 2020, which is a key catalyst for achieving positive Canadian operating cashflow. The Company has also identified additional cost reductions in selling,

general and administrative expenses and operating budgets to partly offset the expected slower revenue ramp. The aggregate impact of these changes on the Company's financial forecasts are described below under the heading "Financial Outlook".

Financial Outlook

The Company disclosed forecasted Canadian operating cash flows for June 1, 2020 to May 31, 2021 in its management's discussion and analysis for the three months ended June 30, 2020. In its October Offering prospectus, the Company updated this forecast and compared it, although it was not for the same time period, to its current forecast for October 1, 2020 to September 30, 2021. The Company withdraws its forecast of Canadian operating cash flows for June 1, 2020 to May 31, 2021 and does not intend to further update it. The Company will update its forecasted Canadian operating cash flows for October 1, 2020 to September 30, 2021 to the extent required by applicable Canadian securities laws. The Company's forecasted Canadian operating cash flows for October 1, 2020 to September 30, 2021 are as follows:

	<i>Notes</i>	<i>\$000s</i>
Gross profit on sales before change in fair value of biological assets	(1)	25,096
Sales & marketing ("S&M") expenses	(2)	(7,051)
Research & development ("R&D") expenses	(3)	(682)
General & administrative ("G&A") expenses	(4)	(13,552)
Other income/loss		(405)
Expected Canadian operating cash flow		<u>3,406</u>

Notes:

The following significant assumptions have been utilized in preparation of these forecasts which are consistent with the forecast disclosed in the Company's October Offering prospectus:

- (1) Gross profit has been forecasted based on, among other things:
 - i. that the Company's products will meet the desired specifications of it and its distribution partners, for instance with regard to THC content and other specifications;
 - ii. that its Hamilton Facility will produce between 8,000 kgs and 9,000 kgs in 2020 and that optimization of production efficiencies will allow the Company to produce between 12,000 kgs and 14,000 kgs in 2021;
 - iii. that pricing of its products and product mix of its sales will remain consistent with its most recent discussions with its distribution partners and provincial boards;
 - iv. that revenue will continue to grow over the next 12 months as the Company increases sales of its key products across Canada, while harvesting and processing cannabis plants currently in their respective grow cycles, in order to build supply of these products into other provinces in the coming months. Revenues to date associated with the Company's key products have been derived predominantly from Quebec based on, among other factors, production limitations due to the lifecycle of the plants and the fact that these key product lines were very recently launched, but as more of the Company's plants reach the end of their growth cycle, additional production allows further sales into the Company's other distribution channels across Canada, which is a key catalyst in the Company achieving positive operating cash flow;
 - v. that the total recreational and medical cannabis market in Canada will grow in line with the expectations of the analysts whose reports the Company has reviewed; and
 - vi. that its cost of sales per product over the coming 12 months is consistent with its current cost of sales per product.
- (2) S&M expenses in total are forecasted to be consistent with recent levels, although decrease in proportion to the revenue expected to be achieved by the Company. The Company has significantly curtailed new plans for extensive media and in-store promotions and is shifting focus to operations to have product available to meet demand.
- (3) Forecasted R&D expenses for the next six months are expected to be in line with R&D expenses reported in the three months ended September 30, 2020, and then to significantly decrease as new products finish development and move to commercialization. The Company plans to use its existing internal staff and not to engage external consultants or research studies, focusing on fewer new product launches and stopping any topicals development.
- (4) Forecasted G&A expenses reflect recent measures taken to reduce costs from those reported in 2019 and periods in 2020 ending on or before September 30. This salaries and benefits reduction arises due to the termination of certain staff in August and September, the extension of the previously announced 20% cut in management salaries into the fourth quarter of 2020 (whereas previous forecasts anticipated management salaries returning to 100% on October 1, 2020), the decision taken to not find temporary replacements for certain staff taking leave between November 2020 and March 2021, nor hire for 3 new positions previously budgeted, and the removal of a 5% pay increase for staff that had been previously budgeted to be implemented on January 1, 2021. Another major component of the Company's G&A expense forecast is the expected transfer of approximately \$1,800 of overhead staff and maintenance costs related to the Quebec Facility from G&A expenses in previous forecasts to cost of goods sold in the forecasts. This is due to the Quebec Facility commencing processing and packaging of the Company's 2.0 products, having moved this from a third-party co-packer as described

above. As a result, these costs – which were previously expensed in G&A as there was not expected to be any related production – are now expected to be recorded into the cost of goods sold and inventory accounts.

With respect to production and sales forecasts, for October 1, 2020 to September 30, 2021, the Company assumes that it will produce 11,080 kilograms of dried cannabis and generate \$64,400 in sales over the 12-month period. There has been notable price compression in recent months across the legal cannabis market in Canada. Accordingly, the Company’s forecast assumes between 5% and 20% of price compression into 2021 across its various product lines. The sales volume forecast consists primarily of a product mix premium flower, mainstream Highly Dutch flower and 2.0 products expected to be sold and includes hash sales. Management believes that the general legal cannabis market will grow, even in the current economic climate, and the Company believes that growth will largely be driven by two consumer segments: those converting from the illicit to the legal market, who tend to be price-sensitive higher volume consumers of dried cannabis flower, and those who are new consumers of cannabis, and who are more likely to consume cannabis products via edible or beverage delivery methods. The Company has experienced the impact of the trend for reduced overall market demand for premium flower as the adult use flower market and expects a greater percentage of mainstream and value brands being sold. The Company’s latest forecast also reflects the shift in its medical business from sales to patients directly to medical wholesaling, such as the Company’s distribution agreement with Medical Cannabis by Shoppers Drug Mart. Medical wholesale generates narrower gross margins compared to direct patient sales. For its Highly Dutch brand, the Company experienced a two-month delay in the national launch of its Highly Dutch brand due to the August harvest challenges, as discussed further above under the heading “Business Objectives and Milestones”. During this time, there have been several new mainstream brands launched, such that the Company has adjusted its forecast for market penetration to be more conservative to reflect increased competition. For teas, the expected velocity of its teas launched in the summer was lower than expected, which the Company believes was partly due to the hot weather and partly due to the challenges in getting certain tea products on time from the third-party co-packer, which led to the decision to move this production into its Quebec Facility, also discussed further under the heading “Business Objectives and Milestones”. As the Company has now launched hash products in Quebec, it has included this product into its new forecasts based on initial orders and indications of demand levels from provincial boards and the market.

The Company expects to expend approximately \$150 in capital expenditures at the Quebec Facility related to electrical work it expects will be completed in November 2020, which over the forecast period will be required to process cannabis 2.0 products as the Company begins to produce new SKUs such as gummies.

The Company’s non-Canadian subsidiaries do not have capital or operating cash flow requirements over the forecast period other than capital the subsidiaries already have and operating cashflows they generate through the conduct of their business.

The Company’s estimates of Canadian operating cash flows over the next 12 months constitute forward looking information related to possible events, conditions or financial performance based on future economic conditions and courses of action. These statements involve known and unknown risks, assumptions, uncertainties and other factors that may cause actual results or events to differ materially. Readers should not place undue reliance on forward looking information, including for the reasons set out under the headings “Cautionary Statement Regarding Forward Looking Information” and “Risk Factors”. Readers should also see also the Company’s discussion under the heading “Business Objectives and Milestones”. The Company believes that there is a reasonable basis for the expectations reflected in the forward-looking statements in this MD&A. However, these expectations may not prove to be correct.

SELECTED OPERATIONAL INFORMATION

SUMMARY OF KEY QUARTERLY HIGHLIGHTS – Q3-2020 as compared to Q3-2019 and Q2-2020

	Q3-2020	Q2-2020	Q1-2020	Q4-2019	Q3-2019	Q2-2019	Q1-2019	Q4-2018
Revenue	\$ 5,710	4,825	3,059	3,250	2,612	2,896	2,406	1,879
Loss from operations	\$ (6,338)	(9,881)	(15,258)	(17,742)	(19,810)	(16,417)	(14,724)	(18,188)
Net loss ⁽¹⁾⁽²⁾⁽³⁾	\$ (76,244)	(9,775)	(73,436)	(144,753)	(20,303)	(16,603)	(14,091)	(18,120)
Comprehensive loss ⁽¹⁾⁽²⁾⁽³⁾	\$ (75,627)	(10,044)	(71,090)	(144,520)	(21,237)	(17,306)	(15,441)	(17,607)
Net loss per share (basic & diluted) ⁽¹⁾⁽²⁾⁽³⁾	\$ (0.20)	(0.03)	(0.23)	(0.52)	(0.07)	(0.06)	(0.05)	(0.07)

(1) During Q3-2020, the Company recorded a non-cash impairment charge of \$67,837 related to its Canadian CGU.

(2) During Q1-2020, the Company recorded a non-cash impairment charge of \$52,765 related to its Canadian CGU and \$3,082 impairment charge related to its investment in Epican.

(3) During Q4-2019, the Company recorded a non-cash impairment charge of \$123,432 related to its Canadian CGU and \$4,296 impairment charge related to its investment in Epican.

Revenues

Revenue recognized in Q3-2020 amounted to \$5,710, an increase of 119% versus the prior year (Q3-2019 - \$2,612) with hemp derived sales by HemPoland of \$1,875 and sales from cannabis products in Canada of \$3,835. Revenue increased by 18% in comparison to Q2-2020 revenue of \$4,825 primarily due to an increase in sales in Canada of \$1,122, due to the entry into the Quebec market with the launch of the Company's Highly Dutch brand which was launched at the end of May 2020 along with the Company's latest tea offerings. Combined with increased infuser sales, quarter over quarter, the Company expects the launch of the Highly Dutch brand and Unite vapes into other provinces to continue to increase revenues in Q4 2020, albeit with potentially lower percentage gross margins achieved than from its premium organic product. The Company is encouraged by the short sales history of Highly Dutch and Ripple dissolvable powders indicating robust demand.

With the effects of the COVID-19 pandemic being felt earlier in Europe than North America, distribution channels in HemPoland are expected to remain materially consistent per quarter until in person retail conditions improve during which the Company is expected to be able to self sustain. Revenues decreased from \$2,041 to \$1,875 at HemPoland in comparison to Q3-2019 primarily due to product mix where lower margin bulk CBD extract products were sold. The main facility in Poland has been fitted to perform toll manufacturing for customers to maximize the use of capacity and proprietary extraction technology.

Gross profit

The Company's gross profit for Q3-2020 was \$3,969 (Q3-2019 - \$1,695) primarily driven by unrealized gains on changes in fair value of biological assets of \$3,220 which is attributed to the expansion into and fully utilizing more grow rooms in Q3-2020 partially offset by increased sales in Canada which carried higher inventory costs expensed from when the Company was previously scaling production and is now being sold through. Canadian cost of sales reflects the absorption of fixed production costs at Hamilton facility during ramp-up in previous quarters such costs should be absorbed over a higher volume of production in coming months now that Hamilton is being fully utilized. In comparison to Q2-2020, gross profit increased by \$2,643 as a result of the increased revenues in Canada and larger unrealized gain on changes in fair value of biological assets in Q3-2020.

Sales and marketing expenses

	Three months ended				Three months ended		
	September 30, 2020	September 30, 2019	Variance to Q3-2019 (\$)	Variance to Q3-2019 (%)	June 30, 2020	Variance to Q2-2020 (\$)	Variance to Q2-2020 (%)
Personnel costs	631	781	(150)	(19%)	596	35	6%
Third party marketing expenses	677	1,625	(948)	(58%)	801	(124)	(15%)
Travel and promotion expenses	44	198	(154)	(78%)	52	(8)	(15%)
Strategic partnership payments	877	676	201	30%	724	153	21%
Other marketing expenses	66	62	4	6%	67	(1)	(1%)
	2,295	3,342	(1,047)	(31%)	2,240	55	2%

Sales and marketing expenses of \$2,295 for the three-months ended September 30, 2020 decreased in comparison to expenses of \$3,342 for the same period in the prior year primarily due to additional work being performed in house with increased efficiencies rather than work performed by external consultants, and less spending on brand development. This is consistent with the Company's plan for cost cutting initiatives in 2020 that were previously announced.

In comparison to Q2-2020, sales and marketing expenses increased marginally in Q3-2020 by \$55. The Company received \$96 in wage subsidies from the CEWS related to S&M from the federal government in response to COVID-19 for eligible periods 1 and 2 in Q2-2020 and made an accounting policy choice to net the proceeds against the related and applicable expenses in accordance with IFRS. The Company applied this policy choice consistently.

Research and development expenses

	Three months ended				Three months ended		
	September 30, 2020	September 30, 2019	Variance to Q3-2019 (\$)	Variance to Q3-2019 (%)	June 30, 2020	Variance to Q2-2020 (\$)	Variance to Q2-2020 (%)
Personnel costs	206	260	(54)	(21%)	232	(26)	(11%)
Product development	70	110	(40)	(36%)	25	45	180%
Travel related expenses	8	53	(45)	(85%)	-	8	n/a
Other research and development expenses	6	118	(112)	(95%)	62	(56)	(90%)
	290	541	(251)	(46%)	319	(29)	(9%)

Research and development expenses of \$290 for the three-months ended September 30, 2020 decreased in comparison to expenses of \$541 for the same period in the prior year. The Company incurred higher R&D costs in the prior year working on new product formulations and has successfully commercialized organic cannabinoid dissolvables in Canada under the TGOD-Infusers line which began selling at the end of Q1-2020. Similar costs were not incurred in Q3-2020 due to the products already being available and spending in line within the Company's cost cutting initiatives.

In comparison to Q2-2020, research and development expenses decreased in Q3-2020 by \$29 primarily due to the aforementioned cost cutting initiatives amongst personnel, product development and limiting travel.

General and administrative expenses ("G&A")

	Three months ended				Three months ended		
	September 30, 2020	September 30, 2019	Variance to Q3-2019 (\$)	Variance to Q3-2019 (%)	June 30, 2020	Variance to Q2-2020 (\$)	Variance to Q2-2020 (%)
Personnel costs	1,971	4,168	(2,197)	(53%)	1,234	737	60%
Office and other administrative expenses	1,358	3,598	(2,240)	(62%)	2,780	(1,422)	(51%)
Third party professional, consulting, legal fees	752	4,975	(4,223)	(85%)	1,313	(561)	(43%)
Computer and IT expenses	289	596	(307)	(52%)	323	(34)	(11%)
Severances	631	-	631	n/a	60	571	952%
	5,001	13,337	(8,336)	(63%)	5,710	(709)	(12%)

G&A expenses of \$5,001 for the three months ended September 30, 2020 decreased in comparison to expenses of \$13,337 for the same period in the prior year. The year-over-year decrease of \$8,336 is mainly related to the reduction of personnel costs and third-party professional, consulting and legal costs.

In comparison to Q2-2020, G&A expenses decreased by \$709 which reflects part of the Company's plan to significantly reduce general and administrative expenses mainly due to reduced spending on third party vendors, partially offset by increased severance costs incurred in the quarter and the fact that the Company received \$342 in CEWS payments in Q2-2020.

Share-based compensation expenses

The Company recognized a share-based compensation expense of \$451 for the three months ended September 30, 2020 compared to \$3,513 for the same period in the prior year. Share-based compensation was valued using the Black-Scholes valuation model and represents a non-cash expense. The decrease is primarily due to a reduction in the grant date fair value of new options granted, which is primarily attributable to the decline in the Company's stock price and market volatility.

In comparison to Q2-2020, share-based compensation expense decreased by \$1,206 primarily due to the cancellation of certain employee options from terminations occurring in Q3-2020.

Loss from operations

Losses from operations were \$6,338 for the three months ended September 30, 2020 compared to \$19,810 for the same period in the prior year primarily driven by (i) increased gross profit (which reflect significant sales in Q3-2020 versus the prior year) (ii) much higher production leading to increases in changes in fair value of biological assets and (iii) the implementation of cost cutting measures, and resulting decreased operating expenses.

In comparison to a loss from operations of \$9,881 in Q2-2020, the Company's losses from operations for Q3-2020 were lower primarily due to reductions in operating expenses and increased gross profits.

Impairment

A non-cash impairment charge of \$67,837 for the three months ended September 30, 2020 (September 30, 2019 – \$Nil) was realized on the Canadian cash generating unit ("Canadian CGU"). The non-cash impairment charges recognized during the period is primarily attributable to changes in the timing of accessing market demand, sales price compression across the industry and the resulting slower revenue ramp up and growth than previously forecasted by management. See "Business Objectives and Milestones". Management has taken steps to realign the strategic plan to account for the changed market conditions. This non-cash impairment charge does not directly impact the Company's operating activities or liquidity.

Net loss

The Company's net loss for the three months ended September 30, 2020 was \$76,244 (September 30, 2019 – \$20,303) which is comprised primarily of the impairment charge and loss from operations discussed above.

Comprehensive loss

The Company's comprehensive loss for the three months ended September 30, 2020 was \$75,627 (three months ended September 30, 2019 – \$21,237) and is comprised of the net loss discussed above and other comprehensive income which comprised of foreign exchange translation gains from foreign operations of \$617 (three months ended September 30, 2019 – loss of \$934).

In comparison to Q2-2020, the Company's comprehensive loss increased by \$65,583 primarily due to the non-cash impairment charge partially offset by lower a loss from operations, as well as fluctuation in exchange rates.

SUMMARY OF YEAR TO DATE ("YTD") RESULTS – YTD-2020 as compared to YTD-2019

The table below summarizes selected information regarding the Company's loss from operations and other financial information for the periods presented in accordance with IFRS and on a consistent basis with the interim consolidated financial statements and related notes:

	For the nine months ended	
	September 30, 2020	September 30, 2019
Revenue	\$ 13,594	\$ 7,913
Loss from operations	\$ (31,477)	\$ (50,951)
Net loss ⁽¹⁾	\$ (159,455)	\$ (50,997)
Comprehensive loss ⁽¹⁾	\$ (156,761)	\$ (53,984)
Net loss per share (basic & diluted) ⁽¹⁾	\$ (0.46)	\$ (0.19)

⁽¹⁾ During the nine months ended September 30, 2020, the Company recorded non-cash impairment charges of \$120,602 related to its Canadian CGU and \$3,082 impairment charge related to its investment in Epican.

Revenues

Revenue recognized for the nine months ended September 30, 2020 amounted to a \$13,594 or 72% increase versus the prior year (nine months ended September 30, 2019 - \$7,913).

Sales from cannabis products in Canada of \$7,212 for the nine months ended September 30, 2020 (nine months ended September 30, 2019 - \$591) represented a significant increase over the prior year given the Company's recreational sales of cannabis in Canada began in Q3-2019. Management believes that while the premium market targeted by the Company in its pilot commercialization initiatives has declined significantly as a proportion of the total Canadian cannabis market over the past year, the Company is adapting to the market dynamics and has increased focus into the mainstream flower market with its Highly Dutch brand, as well as continuing to expand its Cannabis 2.0 product lines. The Company expects the Highly Dutch brand to expand across the rest of the provinces and is making adequate inventory available for a ramp up of sales in Q4-2020. Finally, in relation to Canadian operations, during the nine months ended September 30, 2020, the Company incurred \$1,363 in excise duties thereby reducing gross revenue to arrive at \$5,849 of net revenues in Canada (nine months ended September 30, 2019 - \$87 for excise duties and net revenues of \$504).

Sales from hemp derived products by the Company's wholly owned subsidiary in Poland were \$6,382 (nine months ended September 30, 2019 - \$7,322 related to HemPoland only). The decrease in revenue year over year from HemPoland relates primarily to higher volumes of lower margin bulk CBD extract products being sold at HemPoland during the nine months ended September 30, 2019 and since then has strategically shifted focus away from bulk extracts towards more profitable CannabiGold product lines. Even with the effects of the COVID-19 pandemic being felt in Europe, distribution channels are expected to remain relatively consistent. HemPoland started selling into the United Kingdom and plans to expand into other European markets in the balance of 2020 and is reworking its online sales capabilities to ship products direct to consumer, where applicable, to combat the expected lack of foot traffic in retail locations. In addition, the main facility in Poland has been fitted to perform toll manufacturing for customers to maximize the use of capacity and proprietary extraction technology.

Gross profit

The Company's gross profit for nine months ended September 30, 2020 of \$7,001 was \$1,982 higher than the nine months ended September 30, 2019 primarily because of sales being introduced on a more significant basis in Canada which had higher margins whereas the prior year only had \$504 in net revenue in Canada, in addition to a small decrease in HemPoland net sales and higher cost of sales of products sold from HemPoland in comparison to the prior year. For the nine months ended September 30, 2020, the gross margin before changes in fair value of biological assets was 22% in comparison to 59% for the nine months ended September 30, 2019 where the prior year figure consisted primarily of sales and gross profit from HemPoland.

Sales and marketing expenses

	Nine months ended			
	September 30, 2020	September 30, 2019	Variance to Q3-2019 (\$)	Variance to Q3-2019 (%)
Personnel costs	1,974	1,968	6	0%
Third party marketing expenses	2,388	5,473	(3,085)	(56%)
Travel and promotion expenses	175	651	(476)	(73%)
Strategic partnership payments	2,246	2,085	161	8%
Other marketing expenses	215	91	124	136%
	6,998	10,268	(3,270)	(32%)

Sales and marketing expenses of \$6,998 for the nine months ended September 30, 2020 decreased in comparison to expenses of \$10,268 for the same period in the prior year primarily due to additional work being performed in house rather than by external consultants, hence the slight additional increase in personnel costs during the nine months ended September 30, 2020. This is consistent with the Company's plan for cost cutting initiatives in 2020 that were previously announced. The Company also received \$96 in 2020 related to S&M in wage subsidies from the CEWS.

Research and development expenses

	Nine months ended			
	September 30, 2020	September 30, 2019	Variance to Q3-2019 (\$)	Variance to Q3-2019 (%)
Personnel costs	816	700	116	17%
Product development	181	522	(341)	(65%)
Travel related expenses	30	97	(67)	(69%)
Other research and development expenses	102	244	(142)	(58%)
	1,129	1,563	(434)	(28%)

Research and development expenses of \$1,129 for the nine months ended September 30, 2020 decreased in comparison to expenses of \$1,563 for the same period in the prior year. While year over year, the Company's headcount of professionals who were working on the development of the Company's 2.0 products increased, this expense was more than offset by a reduction in external consultants. The Company has successfully commercialized organic cannabinoid dissolvables in Canada under the TGOD-Infusers line which began selling in the nine months ended September 30, 2020. The Company also received \$45 in 2020 wage subsidies from the CEWS related to R&D.

General and administrative expenses ("G&A")

	Nine months ended			
	September 30, 2020	September 30, 2019	Variance to Q3-2019 (\$)	Variance to Q3-2019 (%)
Personnel costs	7,450	10,035	(2,585)	(26%)
Office and other administrative expenses	6,510	8,778	(2,268)	(26%)
Third party professional, consulting, legal fees	4,295	10,496	(6,201)	(59%)
Computer and IT expenses	887	1,394	(507)	(36%)
Severances	1,361	-	1,361	n/a
	20,503	30,703	(10,200)	(33%)

G&A expenses of \$20,503 for the nine months ended September 30, 2020 decreased in comparison to expenses of \$30,703 for the same period in the prior year. The year-over-year decrease is mainly related to the reduction in headcount and fees paid to third party, consulting, and legal costs, partially offset by severance costs accrued to former employees of \$1,361 (nine months ended September 30, 2019 – immaterial). The Company also received \$342 in 2020 wage subsidies from the CEWS related to G&A.

Share-based compensation expenses

The Company recognized a share-based compensation expense of \$4,578 for the nine months ended September 30, 2020 compared to \$11,365 for the same period in the prior year. Share-based compensation was valued using the Black-Scholes valuation model and represents a non-cash expense. The decrease is primarily due to a reduction in the grant date fair value of new options granted, which is primarily attributable to the decline in the Company's stock price combined with market volatility and cancellations from employment terminations.

Loss from operations

Losses from operations were \$31,477 for the nine months ended September 30, 2020 compared to \$50,951 for the same period in the prior year. The smaller loss related primarily to the factors discussed above where revenues have increased and cost cutting per the Company's revised strategic plan is being implemented.

Impairment

A non-cash impairment charge of \$120,602 for the nine months ended September 30, 2020 (September 30, 2019 – \$Nil) was realized on the Canadian cash generating unit ("Canadian CGU"). The non-cash impairment charges recognized during the period is primarily attributable to the changes in the timing of accessing market demand, sales price compression across the industry and the resulting slower revenue ramp up and growth than originally forecasted by management. Management has taken steps to realign the strategic plan to account for the changing market conditions. In addition, the Company recognized an impairment loss on its investment in Epican of \$3,082 (September 30, 2019 – \$Nil) due to changing market conditions in Jamaica. The Company sold its

interest in the entity during the nine months ended September 30, 2020. The non-cash impairment charge does not directly impact the Company's operating activities or liquidity.

Net loss

The Company's net loss for the nine months ended September 30, 2020 was \$159,455 (September 30, 2019 – \$50,997) which is comprised of the loss from operations and impairment discussed above. In addition, during the nine months ended September 30, 2020, foreign exchange losses amount to \$2,041 (September 30, 2019 - \$683) due to a decrease in the Canadian dollar against the US dollar and European Euro, partially offset by contingent consideration revaluation gain of \$391 (September 30, 2019 - \$42) and finance income of \$340 (lower than September 30, 2019 - \$2,533 because of lower cash on hand generating interest income).

Comprehensive loss

The Company's comprehensive loss for the nine months ended September 30, 2020 was \$156,761 (September 30, 2019 – \$53,984) and was comprised of the net loss discussed above and other comprehensive income comprised of foreign exchange translation gain from foreign operations of \$2,694 (September 30, 2019 - \$2,987 – loss incurred through other comprehensive income).

FINANCIAL POSITION

The table below summarizes selected information regarding the Company's financial position for the periods presented in accordance with IFRS and on a consistent basis with the interim consolidated financial statements and related notes:

	As at September 30, 2020	As at December 31, 2019	As at January 1, 2019*	As at December 31, 2017
Total assets	\$ 211,676	\$ 342,181	\$ 447,236	\$ 96,977
Total non-current liabilities	\$ 18,360	\$ 21,354	\$ 3,591	\$ -
Total shareholders' equity	\$ 139,116	\$ 267,600	\$ 413,655	\$ 77,248

* The Company adopted IFRS 16 – Leases on January 1, 2019 and reflected transitional opening balance sheet adjustments as a result.

The following is a discussion of the significant changes to selected balances in the Company's financial position as at September 30, 2020 as compared to December 31, 2019 in accordance with IFRS and on a consistent basis with the interim consolidated financial statements and related notes:

Assets

The Company's consolidated cash and cash equivalents of \$4,100 as at September 30, 2020 reduced from \$27,569 as at December 31, 2019 primarily as a result of paying down construction and operational payables as described in the "Liquidity and Capital Resources" section. The Company's trade receivables of \$1,934 as at September 30, 2020 (December 31, 2019 - \$1,488) represent increased sales in the month of September 2020 compared to prior months. As at September 30, 2020, the Company had \$18,187 in inventory as compared to \$8,268 as at for December 31, 2019 as a result of recent harvests from the Company's Hybrid Greenhouse and an increase in packaging and supplies purchased to be ready for new upcoming orders. The Company's property plant and equipment decreased by \$93,719 to \$143,314 primarily as a result of \$118,316 in non-cash impairment charges and \$4,142 in depreciation, partially offset by year to date additions of \$30,519 most of which primarily related to construction.

Liabilities

The Company's accounts payable and accrued liabilities, including non-current accrued liabilities was \$24,107 as at September 30, 2020 as compared to \$52,074 as at December 31, 2019 with the decrease primarily relating to payments made against outstanding construction payables funded in part, by additional debt received from the Company's *Senior Secured Credit Facility* and from equity financings undertaken.

The Company's current portion of loans payable amounted to \$29,089 (which also includes the effects of accretion expense) as at September 30, 2020 as compared to \$524 as at December 31, 2019 primarily due to the balance of the Senior Secured Credit Facility that was coming due within twelve months, being the end of June 2021 and thus being reclassified from its 'long term' presentation. The Senior Secured Credit Facility was rescheduled on October 2, 2020 with the maturity date being extended to December 15, 2021. The Company's remaining Loans balance, presented as long-term, was \$12,322 as at September 30, 2020 was payable by October 2021. On November 2, 2020, the Revolver Facility was rescheduled with the repayment date being extended to December 31, 2021.

Equity

The Company's Shareholders' equity decreased from \$267,600 as at December 31, 2019 to \$139,116 primarily due to an increase in the accumulated deficit of \$158,935, an increase in the non-controlling interest of \$520, partially offset by an increase in share capital of \$19,274, contributed surplus of \$9,003, and changes to accumulated other comprehensive income of \$2,694.

LIQUIDITY AND CAPITAL RESOURCES

During the three and nine months ended September 30, 2020, the Company generated its revenue from domestic cannabis and international hemp operations and relied on the equity financings raised together with the additional debt facilities closed to finance its operations and meet its capital requirements. The Company's objectives when managing its liquidity and capital resources are to maintain a sufficient capital base to maintain investor and creditor confidence and to sustain the future development of the business.

As at September 30, 2020 the Company had a consolidated negative working capital of \$19,820 (December 31, 2019 - \$14,939 positive working capital) primarily due to the Company presenting the Senior Secured Credit Facility as a current liability as at September 30, 2020. On October 6, 2020, the Senior Loan was extended to December 15, 2021 and on November 2, 2020, the Revolving Credit Facility was extended to December 31, 2021. The total consolidated cash position was \$4,319, including \$219 of restricted cash held in escrow for construction contracts (December 31, 2019 - \$36,147 of which \$8,578 was restricted cash). This cash, together with additional financing received subsequent to September 30, 2020 will be used primarily towards covering operating costs as the Company moves towards achieving positive Canadian operating cashflow.

The Company has primarily financed its operations to date through the issuance of common shares, warrants, and debt facilities. Although the Company has rescheduled its debt obligations on its Senior Secured Credit Facility and Revolving Credit Facility to December 2021 and obtained other capital through the issuance of equity in October 2020, the Company may need to further reschedule its debt or obtain capital through various means including the issuance of equity and/or debt to repay its obligations. The interim consolidated financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future if revenue plans, debt refinancing and/or additional debt or equity financing or any combination thereof is received. There can be no assurance that additional funding will be available to the Company, or, if available, that this funding will be on acceptable terms. If adequate funds are not available, the Company may be required to delay or reduce the scope of any or all of its projects. These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

	For the three months ended			For the nine months ended		
	September 30, 2020	September 30, 2019	Variance to Q3-2019 (\$)	September 30, 2020	September 30, 2019	Variance to Q3-2019 (\$)
Net cash used in operating activities	\$ (6,704)	\$ 9,518	\$ (16,222)	\$ (28,086)	\$ (36,158)	\$ 8,072
Net cash used in investing activities	(8,814)	(56,420)	47,606	(35,811)	(167,092)	131,281
Net cash provided by financing activities	875	1,361	(486)	39,358	13,482	25,876
Net effects of foreign exchange	(34)	(239)	205	1,070	(846)	1,916
(Decrease) increase in cash and cash equivalents	\$ (14,677)	\$ (45,780)	\$ 31,103	\$ (23,469)	\$ (190,614)	\$ 167,145

Operating Activities

For the nine months ended September 30, 2020 net cash used in operating activities was \$8,072 lower than the nine months ended September 30, 2019. The decrease was primarily related to improved gross profit generated and cost reductions initiatives in the nine months ended September 30, 2020.

Investing Activities

For the nine months ended September 30, 2020 net cash used in investing activities was \$131,281 lower than the nine months ended September 30, 2019. The decrease was primarily the result of requiring less capital used to settle construction contracts as well as extending payment terms with suppliers.

For the three months ended September 30, 2020, net cash outflow consisted primarily of \$9,283, mostly related to payments on deferred payment plans for previously incurred construction, partially offset by the sale of unused equipment for \$975.

Financing Activities

For the nine months ended September 30, 2020, net cash provided by financing activities was \$25,876 higher than the nine months ended September 30, 2019. The increase was primarily the result of \$20,753 proceeds from the two bought deals closed in the period as well as \$22,009 proceeds from the closing of debt facilities during the period compared to the nine months ended September 30, 2019. The increase was primarily offset by a decrease of \$11,707 in cash received related to the exercise of stock options and warrants in comparison to the nine months ended September 30, 2019.

Contractual obligations

The Company had the following estimated gross contractual obligations as at September 30, 2020, which were expected to be payable in the following respective periods:

	Carrying amount	Contractual cash flows - 12 months ending						Thereafter
		Total	September 2021	September 2022	September 2023	September 2024	September 2025	
	\$	\$	\$	\$	\$	\$	\$	\$
Accounts payable and accrued liabilities	24,107	24,107	23,983	124	-	-	-	-
Loans ⁽¹⁾	41,411	51,543	38,019	13,524	-	-	-	-
Lease liabilities	5,927	9,556	1,117	1,033	857	834	752	4,963
Commitments related to construction ⁽²⁾	-	655	655	-	-	-	-	-
Contingent consideration payable	71	107	-	-	107	-	-	-
Total contractual obligations	71,516	85,968	63,774	14,681	964	834	752	4,963

⁽¹⁾ Contractual cash flows include interest payable until the maturity date for the first lien senior secured credit facility amounts outstanding as at September 30, 2020. This table does not include the modifications of its debt subsequent to September 30, 2020. Refer to the description of these transaction in the "Recent Developments" above.

⁽²⁾ Payables related to construction activities that have been incurred are included in accounts payable and accrued liabilities whereas amounts yet to be incurred have no carrying amount as at September 30, 2020.

The Company's accounts payable and accrued liabilities include consolidated trade payables and accrued liabilities for work incurred, including for the construction of the facilities.

The contractual cash flows in the table above include the relevant interest and principal payments related to the total of \$32,200 now drawn on the Senior Secured Credit Facility and the \$13,000 drawn on the Revolver Facility as at September 30, 2020 payable until maturity dates with no pro-forma effects of the modifications subsequent to September 30, 2020. The Company expects further draws of \$12,324, out of the \$17,000 available under the Revolver Facility secured by trade receivables, over the next 12 month period for which it will have to incur interest charges based on actual uses. The Company may repay the principal on the Senior Secured Credit Facility at any time with a 2% penalty on the outstanding principal which is currently \$32,200 as mentioned above.

The Company's leased liabilities are valued in accordance with IFRS where the Company has recognized an increase to both assets and liabilities on the consolidated statements of financial position, as well as a decrease to operating expenses (for the removal of rent expense for leases), an increase to depreciation and amortization (due to depreciation of the right-of-use assets), and an increase to finance costs (due to accretion of the lease liability).

The contingent consideration payable relates to contingent consideration of up to 3,047,723 shares potentially payable to the former owners of HemPoland based on that entity achieving certain earnings targets by the end of the 2021 financial year which may be settled in cash pursuant to the terms of the agreement at the Company's option. The consideration is revalued to fair value at the

end of each reporting period in accordance with IFRS based on a valuation technique with a probability assessment of asymmetric payment structures.

Other Contractual Commitments

The lease for the office space of the Company's headquarters required the issuance of a letter of credit in the amount \$350, which may be drawn upon by the landlord in the event of a material breach of the agreement. As at September 30, 2020, there have been no breaches and no amounts have been drawn upon this letter of credit.

Pursuant to some of the agreements related to the Company's facilities, as at September 30, 2020, the Company has letters of credit in the amount of \$1,800 which may be drawn upon in the event of material breaches of the respective agreements. These letters of credit bear conventional rates of interest partially offset by the interest earned on guaranteed investment certificates ("GIC") securing the letters as collateral. The Company has pledged corresponding GICs as collateral, which has been recorded in other assets. As at September 30, 2020, there have been no breaches and no amounts have been drawn on the letters of credit.

The Company has also entered into certain agreements for equipment and services that allow for deferred payment terms and/or the inclusion of permitted subordinated liens on personal property, per the Senior Loan agreement, associated with the equipment located at both the Hamilton and the Quebec facilities should there be any material breaches of the agreements. As at September 30, 2020, there have been no breaches of the respective agreements.

Claims and Litigation

The Company may become subject to litigation from time to time in the ordinary course of business, some of which may adversely affect its business. For instance, the Company is currently subject to two employment-related claims totalling approximately \$3,125, a breach of contract claim by former warrant holders for approximately \$1,250 million, a civil claim in the United States District Court for the Middle District of Georgia, and a claim from a customer in Europe for approximately \$2,100 million. The employment claims relate to a former contract CFO of the Company and a former consultant to the Company. The former contract CFO issued a claim in the Ontario Superior Court of Justice for damages of \$3,000 on September 25, 2018 and the Company filed a defence in October 2018 where management responded that it believes the claim is without merit. There have been no appearances or proceedings scheduled since the Company's defence was filed. The claim by the former consultant was issued by the Ontario Superior Court of Justice on April 15, 2020, claiming damages of approximately \$125. The Company has filed its defence and the parties are in the process of discussing a schedule to advance the matter. In the breach of contract claim, a group of plaintiffs have brought a claim in British Columbia alleging breach of contract in regard to share purchase warrants they were prevented from exercising due to a restrictive trading period. This matter has been set down for trial commencing July 19, 2021. On August 3, 2020, the Company was named as a defendant in a civil litigation matter commenced in the United States District Court for the Middle District of Georgia relating to its minority interest in a US-based beverage incubation business, seeking, among other things, unquantified compensatory damages and injunctive relief. The Company believes the suit against it is without merit and intends to vigorously defend the matter. Finally, a customer in Europe (a distributor) alleges that HemPoland breached a verbal contract with it by ceasing to cooperate with the distributor and has alleged damages of approximately \$2,100. No proceedings have been initiated in respect of the matter. An action against the Company's subsidiary, HemPoland, brought by a former officer of HemPoland for the payment of severance previously disclosed by the Company was dismissed by the court in Elblag, Poland on September 10, 2020.

Should any of these claims or any other litigation in which the Company becomes involved be determined against the Company, such a decision could adversely affect the Company's ability to continue operating, the value or market price for the Common Shares and could require the use of significant resources. Even if the Company is involved in litigation and is ultimately successful, litigation can require the redirection of significant resources. Litigation may also create a negative perception of the Company's brand.

Use of Proceeds from Previous Financings

The following table compares the Company's previous disclosure on its intended use of proceeds from previous offerings with the subsequent actual use of those proceeds, together with an explanation of any variances and the impact of those variances, if any, on the Company's ability to achieve its business objectives and milestones:

Financing	Disclosed intended use of net proceeds	Actual use of proceeds and discussion of variances
December 2019 Units	To complete the construction of the processing centre at the	Approximately \$3,100 of the net proceeds from the December Offering were used for payments specifically related to the

	<p>Hamilton Facility - \$14,200 net of transaction costs</p> <p>Working capital - \$7,510 net of transaction costs</p>	<p>construction of the Hamilton Facility, with the balance of the net proceeds being applied toward working capital.</p> <p>Subsequent to the completion of the December Offering, the Company closed the first tranche of its senior secured credit facility on December 24, 2019. The Company's December 13, 2019 stated that the Company anticipated using the proceeds of this facility for capital expenditures required for the completion of the Quebec Facility, for working capital and general corporate purposes and to pay permitted fees and expenses. However, the lender directed the Company to apply the proceeds of the facility to be specifically applied to the construction of the Hamilton and Quebec Facilities in priority to the other intended uses; accordingly, the funds advanced were used for construction payments at both of the Hamilton Facility and the Quebec Facility and additional draws were available to the Company in the first quarter of 2020 to continue construction. As a consequence of the use of a portion of the credit facility advances for construction at the Hamilton Facility, a corresponding amount of the funds from the December Offering were available and used for working capital purposes.</p> <p>The cost of completion of the processing centre at the Hamilton Facility aligned with the Company's previously disclosed expectations in relation to the December Offering; the processing centre at the Hamilton Facility was completed on disclosed anticipated timeline and budget. The Company used the proceeds of the December Offering together with the proceeds of the first tranche of the senior secured credit facility to fund the Company's operations through April 2020.</p> <p>The Company's actual use of proceeds from the December Offering differed significantly from the disclosed intended use of proceeds as a result of differing allocation of funds among financing sources. However, in aggregate, the Company is in the position disclosed as its expectation in the prospectus for the December Offering, in that it has completed the processing centre at the Hamilton Facility on the timeline and at the cost disclosed in the prospectus for the December Offering and used the proceeds of the December Offering together with the proceeds of the first tranche of the senior secured credit facility to achieve this milestone and fund its operations through April 2020.</p>
April 2020 Units	<p>Activities in furtherance of development and launch of key product lines including teas and a mainstream-priced dried organic cannabis flower brand - \$3,880, net of transaction costs</p> <p>General corporate purposes - \$640, net of transaction costs</p>	<p>The Company has applied the approximately \$5,750 of gross proceeds from its public offering of units by short form prospectus dated April 22, 2020 (the "April Offering") substantially as disclosed in that prospectus. The Company contemplated development and launch of its key product lines on the timeline and at the cost disclosed in that prospectus, and used and is using the net proceeds of the April Offering together with the initial proceeds under the revolving credit facility and the first accordion payment under the senior secured credit facility to achieve this development milestone as anticipated.</p>
June 2020 Units	<p>Repayment of construction indebtedness and other</p>	<p>The Company received the proceeds from its public offering of units by short form prospectus dated June 9, 2020 (the "June</p>

	payables - \$11,523, net of transaction costs Negative Canadian operating cash flow - \$2,243, net of transaction costs General corporate purposes - \$153	Offering”) on June 12, 2020. the Company contemplated funding its operations, including the repayment of indebtedness incurred in the construction of the Hamilton Facility and Quebec Facility and other payables and funding for negative Canadian operating cash flows, until achieving positive Canadian operating cash flows in August 2020. The Company used the net proceeds of that offering together with its other financial resources substantially as disclosed in the June 9, 2020 prospectus, including the repayment of indebtedness. However, the Company has not yet achieved positive Canadian operating cash flows for the reasons set out under the heading “Business Objectives and Milestones”.
--	--	---

OFF-BALANCE SHEET ARRANGEMENTS

As at the date of this MD&A, the Company had no material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the financial performance or financial condition of the Company.

CRITICAL ACCOUNTING ESTIMATES, JUDGEMENTS AND CHANGES IN ACCOUNTING POLICIES

Except as disclosed in Note 3 to our interim consolidated financial statements, there were no significant changes in our accounting policies and critical accounting estimates for the three and nine months ended September 30, 2020. We describe our significant accounting policies and critical accounting estimates in Note 3 to the audited consolidated financial statements and MD&A for the year ended December 31, 2019. The preparation of the interim consolidated financial statements requires the use of estimates and judgements that affect the application of the Company’s accounting policies and reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods effected.

FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

[a] Fair values

The Company’s financial instruments were comprised of the following as at September 30, 2020: cash and cash equivalents; restricted cash; refundable sales tax receivable; trade receivables; due from related parties; other investments, other current assets; accounts payable and accrued liabilities; short-term loans; contingent consideration and lease liabilities.

The fair values of the financial assets and financial liabilities are determined at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The assumption for the instrument’s recorded at amortized costs that the instruments fair values approximate their carrying amounts is largely due to the short-term maturities of these instruments.

[b] Fair value hierarchy

Financial instruments recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value. During the three and nine months ended September 30, 2020, there were no transfers of amounts between levels (three and nine months ended September 30, 2019 – no changes).

[c] Management of key risks arising from financial instruments

Credit Risk

As at September 30, 2020, the Company’s trade receivables are primarily concentrated in Canada with the exception of \$771 in Europe. The Company had one customer whose balance was individually greater than 10% of total trade receivable as at September 30, 2020 (December 31, 2019 – one customer).

RELATED PARTY TRANSACTIONS

Identification of related parties

Related parties as at September 30, 2020 have been identified as follows:

Related party	Business relationship	Measurement basis
Jeffrey Scott	Director	Exchange amount
Nicholas Kirton	Director	Exchange amount
Marc Bertrand	Director	Exchange amount
Jacques Dessureault	Director	Exchange amount
Caroline MacCallum	Director	Exchange amount
Brian Athaide	Management, Director	Exchange amount
Sean Bovingdon	Management	Exchange amount
Matthew Schmidt	Management	Exchange amount
Anna Stewart	Management	Exchange amount
Michel Gagne	Management	Exchange amount
9371-8633 Québec Inc.	Non-controlled investee	Exchange amount

Key transactions with related parties

There have been no material transactions with related parties and no unusual transactions outside of the normal course of business in Q3-2020 other than as previously disclosed. Beginning in Q2-2020, Directors of the Company have voluntarily accepted a 20% reduction in their fees. None of the balances outstanding to related parties as at September 30, 2020 are secured (September 30, 2019 – none). No expense has been recognized in the current year or prior year for bad or doubtful debts in respect of amounts owed by related parties. No new guarantees have been given or received by related parties during the three and nine months ended September 30, 2020. As at September 30, 2020, the Company had no receivable or payable balances with key management personnel and \$78 of director fees payable.

Other

Management has accrued termination benefits to former executives that have left the Company to the extent required by IFRS and are no longer considered related to the entity.

On May 25, 2020, the Company sold its interest in EML to another shareholder of EML for a nominal amount given its history of operating losses, recent economic developments in Jamaica restricting operations and the Company’s strategic decision to no longer pursue opportunities in Jamaica to focus on Canadian operations. EML issued the Company a promissory note for the balance of \$449 as at September 30, 2020.

REGULATORY LANDSCAPE

The results of operations and financial condition of the Company are subject to a number of regulations and are affected by a number of factors outside the control of management.

Canadian Regulatory Landscape

Cannabis production, distribution, sale, and use is illegal in Canada except where specifically permitted by law. On October 17, 2018, the federal Cannabis Act and accompanying Regulations, including the Cannabis Regulations (“Cannabis Regulations”), the new Industrial Hemp Regulations (“IHR”, and together with the Cannabis Regulations, collectively, the “Regulations”), came into force, legalizing the production, distribution and sale of cannabis for adult recreational purposes, as well as incorporating the pre-existing medical cannabis regulatory scheme under one complete framework. Amendments legalizing the sale of edible cannabis, cannabis extracts, and cannabis topicals in the Canadian market came into force on October 17, 2019. A federally licensed entity with authorization to produce and sell edible cannabis, cannabis extracts, and cannabis topicals must provide 60-days notice to Health Canada of its intent to sell these newly legalized classes of products.

Pursuant to the federal regulatory framework in Canada, each province and territory may adopt its own laws governing the distribution, sale and consumption of cannabis and cannabis accessories within the province or territory. All Canadian provinces and territories have implemented mechanisms for the distribution and sale of cannabis for recreational purposes within those jurisdictions, and retail models vary between jurisdictions.

The Cannabis Act maintains separate access to cannabis for medical purposes, including providing that import and export licences and permits will only be issued in respect of cannabis for medical or scientific purposes or in respect of industrial hemp. Patients who have the authorization of their healthcare provider have access to cannabis, either purchased directly from a federally licensed entity authorized to sell for medical purposes, or by registering to produce a limited amount of cannabis for their own medical purposes or designating someone to produce cannabis for them.

Provincial Regulatory Framework for Recreational Cannabis

While the Cannabis Act provides for regulation of the commercial production of cannabis and related matters by the federal government, the provinces and territories of Canada have authority to adopt their own laws and regulations governing the distribution, sale and consumption of cannabis and cannabis accessory products within the province or territory, permitting for example, provincial and territorial governments to set lower possession limit for individuals and higher age requirements. Currently each of the Canadian provincial and territorial jurisdictions has established a minimum age of 19, except for Alberta, where the minimum age is 18, and Québec, where the minimum age is 21.

All Canadian provinces and territories have implemented regulatory regimes for the distribution and sale of cannabis for recreational purposes within those jurisdictions. Provincial/territorial bodies act as intermediaries between entities licensed federally under the Cannabis Act and consumers, such bodies acting in some jurisdictions as exclusive cannabis wholesalers and distributors, and in some instances as exclusive retailers.

Some municipal and regional governments may also choose to impose additional requirements and regulations on the sale of recreational cannabis. In some provinces, municipal by-laws may restrict the number of recreational cannabis retail outlets that are permitted in a certain geographical area, or restrict the geographical locations wherein such retail outlets may be opened.

Regulatory Landscape Outside Canada

The Company only conducts business in jurisdictions outside of Canada where such operations are legally permissible in accordance with all of the laws of the foreign jurisdiction, the laws of Canada and the rules of the TSX. The legal and regulatory requirements in the foreign countries in which the Company operates with respect to the cultivation and sale of cannabis, as well as local business culture and practices, are different from those in Canada. Prior to commencing operations in a new country, in partnership with local legal counsel, consultants and partners, the Company conducts legal and commercial due diligence in order to ensure that the Company and its officers and directors gain a sufficient understanding of the legal, political and commercial framework and specific risks associated with operating in such jurisdiction. Where possible, the Company seeks to work with respected and experienced local partners who can help the Company to understand and navigate the local business and operating environment, language and cultural differences. In consultation with advisors, the Company takes steps deemed appropriate in light of the level of activity and investment it expects to have in each country to ensure the management of risks and the implementation of necessary internal controls.

Denmark

As of January 1, 2018, the Danish government initiated a trial (“pilot program”) permitting doctors to prescribe medical cannabis to a defined patient group. The trial will continue for the next four years and is supported by federal funding. The Danish

Medicines Agency issues licences to import “primary” (starter) cannabis products and to cultivate (as of July 1, 2018) and produce approved forms of medical cannabis for wholesale distribution within Denmark (sale at Danish pharmacies). The Danish government initiated a four-year development scheme so that the Danish Medicines Agency authorizes research and development activities in terms of cultivating and handling cannabis, which may form part of the pilot program at a later stage. All medical cannabis production facilities and products are subject to inspection by the Danish Medicines Agency. As of January 1, 2019, export of cannabis bulk and primary products is also included in the pilot program. Exporting activities relating to cannabis bulk or primary products must be in accordance with requirements laid down in the legislation, including obtaining the necessary authorization. The country receiving the cannabis bulk must allow import of cannabis for medicinal use and the company importing the cannabis bulk or primary products must have the necessary authorizations in place according to national requirements in the importing country.

Since being introduced, there has been debate regarding whether the pilot program has provided medical patients with sufficient access to medical cannabis and whether the implementation and evaluation criteria has been sufficiently clear. An overall review and evaluation of the cannabis pilot program was planned to be carried out in May 2020, but due to the Covid19 crisis, the evaluation has been delayed. The Minister of Health, Magnus Heunicke, has stated that he is ready to extend the medical cannabis pilot program if necessary, for effective evaluation of the program.

Poland

In Poland, the use of hemp is generally restricted and may be accepted only if certain statutory requirements are met. Polish laws provide specific regulations, depending on the use of the hemp. Pursuant to the Misuse of Drugs Act, hemp may be grown solely and exclusively for the needs of the textile, chemical, pulp and paper, food, cosmetic, pharmaceutical and construction industries, as well as for seed production. Buying hemp from a farmer requires a permit from the governor of the province holding territorial jurisdiction over the plantation. Buying and reselling hemp seeds is subject to notification to the appropriate Provincial Inspector of Plant Health and Seed Inspection. Where hemp extracts are used for producing foodstuffs, the production facility must meet the sanitary requirements stipulated under the Act on the Safety of Food and Nutrition. The cultivation of cannabis which does not fall within the definition of hemp under the Misuse of Drugs Act, i.e. “plant species *Cannabis Sativa* L., in which the total content of delta-9-tetrahydrocannabinol and tetrahydrocannabinolic acid (delta-9-THC-2-carboxylic acid) in the floral or fructifying tops of the plants, from which resins has not been removed, does not exceed 0.20% of the dry-extract content” is prohibited in Poland.

Mexico

On June 19, 2017, Mexico enacted certain amendments to the General Health Law of Mexico, allowing the use of cannabis and its derivatives for medicinal purposes that could be commercialized and prescribed by any licensed physician and sold in pharmacies, as long as the products contain less than 1% THC, as well as for the sale of other products with broad industrial uses as long as a cumulative dose of 1% THC is not exceeded. The authority overseeing medicinal cannabis regulations in Mexico is the Mexican Ministry of Health through the Federal Commission for the Protection against Sanitary Risks (“COFEPRIS”). On October 30, 2018, the Guidelines on Health Control of Cannabis and its Derivatives were issued by COFEPRIS regulating medicinal cannabis and allowing the sale of food, food supplements, alcoholic and non-alcoholic beverages without a medical prescription, as long as a cumulative dose of 1% THC is not exceeded, however, the guidelines were revoked on March 27, 2019. On August 14, 2019, Mexico’s Supreme Court of Justice (the “Supreme Court”) resolved an amparo trial setting forth an obligation for the Ministry of Health to regulate the medical and therapeutic use of cannabis and its derivatives, in order to guarantee the human right to health to the public at large. On October 18, 2019 a Bill was presented in Congress by the United Commissions of Justice, Health, and Legislative Studies of the Senate in order to enact the Law for the Regulation of cannabis and the amendments to certain provisions set forth in the General Health Law and the Criminal Code (the “Bill”). On April 17, 2020, Mexico’s Supreme Court of Justice granted a second extension of the deadline for the enactment of such regulations, because of the measures ordered by Mexico’s Government to prevent and combat the spread of the COVID-19. The legal timeframe for the revision of the Bill is running from September 1st until December 15th, 2020, corresponding to the current ordinary period of sessions. The Bill regulates the following uses of cannabis and its derivatives: personal, recreational, medical and palliative, scientific, research, commercial and industrial. Regarding the medical, therapeutic and palliative uses of cannabis’ derivatives, the Bill authorizes the use and production of cannabis, as well as the import and export of products which contain its derivatives. A specific license will be needed for carrying out such activities. Notwithstanding the above, on July 27, 2020, a new draft of the Regulation of Sanitary Control for the Medical Production, Research and Use of Cannabis and its Pharmacological Derivatives (the “Regulation”), was published on the National Commission of Regulatory Improvement’s (“CONAMER”) website. The Regulation was submitted by the Ministry of Health, in compliance of its obligation to regulate the medical use of cannabis according to the ruling enacted by the Supreme Court. The Regulation aims at regulating, control and monitoring, health matters of raw material, molecular complexes, pharmacological derivatives and medicines for the production, research, industrial and medical purposes of cannabis. However, it fails to determine whether foreign investments will be allowed or limiting the percentage of investment of such companies, the

exclusivity of the companies for the obtainment of licenses and authorizations, as well as, the number of licenses that can be obtained by companies or establishments, for one or all the regulated activities. The Regulation was sent back to the Ministry of Health to amend the draft with the comments received by third parties. The deadline for the Ministry of Health to publish the Regulation ended in September 2020; however, to the date hereof, the Regulation has not been published. On October 27, 2020 a new Bill was presented in the Congress by the Federal Congressman Mario Delgado of MORENA's Political Party, to enact the General Law for the Regulation of Cannabis and the amendments to certain provisions set forth in the General Health Law and the Criminal Code (the "new Bill"), such document was sent to diverse Commissions to be reviewed during this ordinary period of sessions, which ends on December 15th, 2020, as it was previously mentioned. The new Bill regulates the following uses of cannabis and its derivatives: personal, medicinal, therapeutic and scientific, likewise, the sanitary control. It comprises the following types of licenses: i) harvest (personal, therapeutic and medicinal uses), ii) acquisition for medicinal purposes (production, transport and storage), iii) production for personal purposes, iv) production for therapeutic and palliative purposes (storage and sale), v) sale for personal purposes (storage and commercialization to costumers for personal use), vi) sale for therapeutic and palliative purposes (storage and commercialization to costumers) and, vii) transport. The new Bill does not determine whether foreign investments will be allowed not even limiting the percentage of their investment. It also does not establish the requirements and uses allowed for the import and export licenses. In addition, the new Bill provides limitations for cross ownership of licenses such that a related group of entities cannot hold licenses that cover more than one type of activities. It is important to note that the new Bill sets forth that communities will have at least 20% of the granted licenses for the production and sale of cannabis and its derivatives and also states that the Government through the "CANNALSUD" (a new public company authorized to acquire and sell cannabis to interested parties such as pharmaceutical industry), will be in charge of the cannabis market in Mexico and the issuance of the licenses.

United States

"Marijuana" is a Schedule I controlled substance under the United States Controlled Substances Act of 1970. On December 20, 2018, hemp (defined as cannabis with not more than 0.3% THC) was removed from Schedule I of the list of controlled substances under United States federal law in accordance with the United States Agriculture Improvement Act of 2018, commonly known as the "2018 Farm Bill". The 2018 Farm Bill does not affect any other cannabis product and therefore cannabis and cannabis derivatives that do not meet the definition of hemp, and activities involving them, remain illegal under United States federal law. On October 29, 2019, the United States Department of Agriculture (the "USDA") released an interim final rule for regulations governing hemp production in the United States. The Farm Bill also authorizes individual states to regulate hemp in their jurisdiction by developing and seeking USDA approval of a regulatory plan. The interim final rule was open to public comment until January 29, 2020. Following review of public comment, the USDA has indicated it intends to publish and implement a final rule governing hemp production. Until the final rule comes into force or state and tribal plans are approved and implemented, the production of hemp remains subject to the provisions of the 2014 Farm Bill, which permits production only for research purposes pursuant to a state pilot program. In addition, notwithstanding the 2018 Farm Bill, the United States Food and Drug Administration (the "FDA") prohibits cannabis (including hemp) and its derivatives, including cannabidiol (CBD), for use as an ingredient in food and drink. The FDA held a public hearing on May 31, 2019, to obtain input from stakeholders regarding the regulation of products containing cannabis and cannabis derivatives. The FDA has not yet indicated whether its approach to the regulation of such products will change in light of the descheduling of hemp or other developments. In addition, any ingredient derived from hemp in food is subject to the premarket approval requirements applicable to food additives, unless that use is generally recognized as safe ("GRAS"). The FDA has issued letters of no objection to at least three GRAS notices for ingredients derived from hemp seed that contain trace amounts of THC and CBD but has not to date addressed whether hemp-derived THC, CBD or other cannabinoids in non-trace levels are GRAS.

Germany

In March 2017, the German legislator introduced "The Cannabis as Medicine Act" ("Gesetz zur Änderung betäubungsmittelrechtlicher und anderer Vorschriften") which regulates the requirements for the marketability of cannabis pharmaceuticals and their inclusion in health insurance plans. Under this Act, statutory insured patients suffering from a severe disease (i.e. life-threatening or seriously affecting quality of life) are entitled to treatment with medicinal cannabis (flowers or extracts in standardized quality) if (i) generally recognized treatment in accordance with medical standards is either not available, or cannot be applied in individual cases according to the justified assessment of the treating physician, and (ii) if there is a not entirely distant prospect of a noticeable positive effect on the course of the disease or on serious symptoms.

Importers of cannabis pharmaceuticals which have not been produced in an EU/EFTA Member State and which shall be distributed in Germany on a commercial or professional basis must apply for an import authorization to the competent health authority in the federal state (Bundesland) in which the importer is based. Generally, the import authorization can be issued for cannabis from cultivations controlled by the State pursuant to the requirements of the 1961 UN Single Convention on Narcotic Drugs. Additionally, importers must apply for a manufacturing authorization pursuant to section 13 Medicinal Products Act

(Arzneimittelgesetz –"AMG") if they carry out at least one manufacturing step within the meaning of section 4 (14) AMG (e.g. preparing, formulating, treating or processing, filling, decanting, packaging, labelling) after import. Furthermore, the distribution of drug products treated with radiation (e.g. E-Beam) requires a permit under the German Regulation on Drug Products treated with Radiation (Verordnung über radioaktive oder mit ionisierenden Strahlen behandelte Arzneimittel – "AMRadV").

The marketing of medicinal cannabis products that qualify as finished medicinal products requires a marketing authorization issued by the competent Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte – "BfArM").

Pursuant to sec. 72a AMG, importers of medicinal cannabis must ensure that their products have been produced in compliance with applicable quality standards and must obtain a written confirmation from a competent authority to prove compliance. In particular, cannabis medicinal products must be manufactured in compliance with the manufacturing standards of the Pharmaceuticals and Active Agent Manufacturing Ordinance (Arzneimittel- und Wirkstoffherstellungsverordnung – "AMWHV"). In addition to standards for the production of the cannabis plant itself, specific pharmaceutical quality standards must be met before placing the product on the market. Such standards are established by pharmaceutical monographs, which are published by the BfArM in the German Pharmacopoeia (Deutsches Arzneibuch – "DAB").

Finally, medicinal cannabis products with a THC concentration of at least 0.2 percent qualify as narcotics under German law and are therefore subject to the authorization requirements under the German Narcotic Drugs Act (Betäubungsmittelgesetz –"BtMG"). Under this Act, seller and buyer of medicinal cannabis products must obtain an authorization by the BfArM. Such an authorization has been issued per se for qualified doctors and pharmacists who sell or buy narcotics for the treatment of a patient or in the course of the operation of a pharmacy.

RISK FACTORS AND UNCERTAINTIES

Many factors could cause the Company's results of operations, performance and financial condition to differ materially from those expressed or implied by the forward-looking statements and forward-looking information contained in this management's analysis and discussion, including the following factors, which are discussed in greater detail under the heading "Risk Factors" in the Company's current Annual Information Form as updated by subsequent reports, filed with securities regulators and available on www.sedar.com, which risk factors are incorporated by reference into this document and should be reviewed in detail by all readers:

- the Company's ability to continue as a going concern;
- the assumptions used in estimating Canadian operating cash flows from October 1, 2020 to September 30, 2021 may prove inaccurate;
- the Company's business is dependent on key supply chains which could be adversely disrupted by a number of factors including, among others, major health issues or pandemics, such as the COVID-19 pandemic;
- The Company's ability to raise required additional capital through the sale of equity or debt instruments or the factoring of receivables or otherwise;
- the Company's limited operating history;
- the Company may be unable to achieve revenue growth and development;
- there are factors which may prevent the Company from the realization of growth targets;
- the Company's actual financial position and results of operations may differ materially from the expectations of the Company's management;
- the Company's CBD business in Europe is subject to evolving approaches to the regulation of CBD by the European Union, its member states, and the United Kingdom;
- the Company expects to incur significant ongoing costs and obligations related to its investment in infrastructure, growth, research and development, regulatory compliance and operations;
- there is no assurance that the Company will turn a profit or generate immediate revenues;
- the adult-use cannabis market in Canada is a relatively new industry;
- the adult-use cannabis market in Canada may experience supply and demand fluctuations that could result in revenue and price decreases;
- the cannabis market in Canada may be significantly reduced over time due to personal cultivation;
- the size of the Company's target market is difficult to quantify, and investors will be reliant on their own estimates on the accuracy of market data;
- the Company is subject to changes in laws, regulations and guidelines which could adversely affect the Company's future business, financial condition and results of operations;

- the Company is reliant on regulatory approvals and cultivation Licenses for its ability to grow, process, package, store and sell cannabis and other products derived therefrom, and these regulatory approvals are subject to ongoing compliance requirements, reporting obligations and fixed terms requiring renewal;
- any failure on the Company's part to comply with applicable regulations could prevent it from being able to carry on its business and there may be additional costs associated with any such failure;
- under Canadian regulations, a Licensed Producer of cannabis is restricted regarding the type and form of marketing it can undertake which could materially impact sales performance;
- the Company intends to target a premium segment of the adult-use cannabis market, which may not materialize, or in which it may not be able to develop or maintain a brand that attracts or retains customers;
- the Company's industry is experiencing rapid growth and consolidation that may cause the Company to lose key relationships and intensify competition;
- the Company may be unsuccessful in competing in the overall legal adult-use cannabis market in Canada and any other countries it intends to operate in;
- the Company, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception;
- the Hamilton Facility and the Québec Facility are expected to become integral to the Company's business and operations;
- there can be no assurance that the Company will receive the required approvals with respect to the Québec Facility;
- the Company may not be able to develop its products, which could prevent it from ever becoming profitable;
- if the Company is unable to develop and market new products, such as beverages, it may not be able to keep pace with market developments;
- there has been limited study on the health effects of cannabis products, including CBD, and future clinical research studies may lead to conclusions that dispute or conflict with the Company's understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of such products;
- trade of cannabis for non-medical purposes within Canada may be restricted by the Canadian Free Trade Agreement;
- the Company is exposed to risks relating to the laws of various countries as a result of its planned international operations;
- the Company's business is subject to a variety of foreign laws, many of which are unsettled and still developing, and which could subject it to claims or otherwise harm its business;
- the Company must rely on international advisors and consultants in the foreign countries in which it intends to operate;
- the Company is required to comply concurrently with federal, state or provincial, and local laws in each jurisdiction where it operates or to which it exports its products;
- the hemp and CBD industries and markets are new and heavily regulated with rules subject to rapidly changing laws and uncertainty, compliance with which may come with significant cost;
- the hemp and CBD products industries and markets in Canada, the EU, Jamaica and Mexico are also subject to many of the same risks as the adult-use cannabis industry and market;
- if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the cannabis market;
- the Company has entered into and in the future may seek to enter into strategic alliances including contractual relationships, joint ventures, selective acquisitions, licensing arrangements or other relationships, or expand the scope of currently existing relationships, with third parties that the Company believes will have a beneficial impact, and there are risks that such strategic alliances or expansions of the Company's currently existing relationships may not enhance its business in the desired manner;
- the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations;
- the cultivation of cannabis includes risks inherent in an agricultural business including the risk of crop loss, sudden changes in environmental conditions, equipment failure, product recalls and others;
- the Company is reliant on key inputs, such as water and utilities, and any interruption of these services could have a material adverse effect on the Company's finances and operation results. The Company is also dependent on access to skilled labour, equipment and parts;
- the Company is vulnerable to rising energy costs;
- the Company's products may not have, or may not be perceived to have, the effects intended by the end user;
- the Company's quality control systems may not operate effectively;
- the Company's cannabis products may be subject to recalls for a variety of reasons, which could require it to expend significant management and capital resources;
- the Company faces an inherent risk of exposure to product liability;
- the Company may be subject to liability claims as a result of positive testing for THC or banned substances;
- consumer preferences may change, and the Company may be unsuccessful in retaining customers;
- the Company's operations are subject to safety, health and environmental laws and regulations applicable to its operations and industry in the various jurisdictions in which it operates, and it may be held liable for any breaches of those laws and regulations;

- the Company could be liable for fraudulent or illegal activity by its employees, contractors and consultants resulting in significant financial losses or claims against the Company;
- the Company may become subject to litigation in the ordinary course of business;
- the Company will be reliant on information technology systems and may be subject to damaging cyber-attacks;
- the Company may be exposed to liability or the threat of liability in relation to the use of customer information and other personal and confidential information;
- the Company may be subject to risks related to the protection and enforcement of its intellectual property rights, or intellectual property it licenses from others, and may become subject to allegations that it or its licensors are in violation of intellectual property rights of third parties;
- the Company may be subject to breaches of security at its facilities;
- the Company may incur additional indebtedness;
- the Company may not be able to secure adequate or reliable sources of funding required to operate its business or increase its production to meet consumer demand for its products;
- management may not be able to successfully implement adequate internal controls over financial reporting;
- the Company currently has negative operating cash flow;
- the Company may be subject to credit risk;
- the Company's loans may contain covenants that limit its ability to seek additional financing or perform desired business operations;
- tax and accounting requirements may change in ways that are unforeseen to the Company and it may face difficulty or be unable to implement or comply with any such changes;
- fluctuations in foreign currency exchange rates could harm the Company's results of operations;
- if the Company has a material weakness in its internal controls over financial reporting, investors could lose confidence in the reliability of the Company's financial statements, which could result in a decrease in the value of its securities;
- it is anticipated that no cash dividends will be paid to holders of Common Shares for the foreseeable future;
- the Company continues to sell shares for cash to fund operations, expansion, and mergers and acquisitions that will dilute the current shareholders;
- the price of the Common Shares in public markets may experience significant fluctuations;
- if securities or industry analysts do not continue to publish research, or publish inaccurate or unfavourable research, about the Company's business, the Common Share price and trading volume could decline; and
- U.S. border officials could deny entry into the U.S. to employees of or investors with cannabis operations in the United States and Canada.

In addition, the Company highlights the following risk factors:

Ongoing Impact of COVID-19:

The development and operation of the Company's business is dependent on labour inputs which could be adversely disrupted by the ongoing impact of COVID-19. While it is difficult to predict the impact of the coronavirus outbreak on the Company's business, measures taken by the Canadian and Ontario governments and voluntary measures undertaken by the Company with a view to the safety of the Company's employees, may adversely impact the Company's business, for instance by impeding the labour required to cultivate, process, market and distribute the Company's products and disrupting the Company's critical supply chains. In addition, while cannabis retail has been declared an essential service in many provinces, sales volumes of cannabis may be adversely impacted by consumer "social distancing" behaviours. All Company office staff had transitioned to working remotely from home offices, with business continuing to be conducted by telephonic and electronic means. In July 2020, the Company reopened its head office on a voluntary and limited basis for its employees. The Company's Hamilton Facility has implemented precautionary measures to ensure the safety of the staff and product, including limiting visits to the site to essential personnel only, ensuring proper protocols around sanitation, mask usage and physical distancing, and placing potentially exposed employees in self-quarantine for the appropriate period. These measures and similar measures taken by other employers may adversely impact the Company's ability to successfully market its new key product lines, for instance by precluding in-store visits and budtender engagement programs. In the short term, the Company is seeking to mitigate these impacts through technology-mediated engagement with retailers. The Company continues to dynamically monitor developments in order to adapt and respond in order to protect the health and safety of the Company's employees and the best interests of the Company, and is in the process of developing return to work protocols for the anticipated easing of provincial pandemic restrictions over the coming months.

Assumptions related to cash flows and future sales of the Company's product lines

The Company expects to be required to fund negative Canadian operating cash flows prior to achieving positive Canadian operating cash flows and expects that the Company's financial resources and expected revenues and draw downs on its revolving credit facility, will be sufficient to pay its obligations and fund its operations for the coming 12 months. Achieving positive

Canadian operating cash flows and funding operations for the coming 12 months is reliant on revenues and working capital requirements being in line with expectations, which is in turn reliant on, among other things, future sales of the Company's product lines over the coming 12 months. The Company's expectations of positive Canadian operating cash flows and of achieving sufficient revenues to fund, when taken together with its other financial resources, its operations over the coming 12 months is based on a variety of assumptions relating to production and production capacity, growth in the number of product offerings and store locations in which the Company's products are sold, growth in total sales, consumer demand for the Company's products, market pricing of cannabis products, cost of sales, sales and marketing expenses, the pace of opening of and increase in the total number of recreational cannabis retail stores across Canada, and the total size of the Canadian recreational and medical cannabis markets over the coming 12 months. In particular, the Company has assumed and expects that, among other things: (i) its products will meet the specifications of it and its distribution partners, for instance with regard to THC content; (ii) pricing of its products will be consistent with its most recent discussions with its distribution partners; (iii) its Hamilton Facility will produce between 8,000 kgs and 9,000 kgs in 2020 and that optimization of production efficiencies will allow the Company to produce between 12,000 kgs and 14,000 kgs in 2021; (iv) that its cost of sales per gram will be consistent over the coming 12 months with its current cost of sales per gram; (v) that its general and administrative expense run rate during the twelve months from October 1, 2020 to September 30, 2021 will be approximately \$13,700, consistent with cost reduction measures taken by the Company; (vi) that certain sales and marketing expenses are expected to increase if the Company achieves increased sales; and (vii) that the total recreational and medical cannabis market in Canada will grow in line with the expectations of the analysts whose reports the Company has reviewed.

Actual results may vary materially from the Company's expectations if any of the Company's assumptions are inaccurate. Accordingly, readers should not place undue reliance on forward-looking statements, including the Company's expectations relating to future Canadian operating cash flows and sales of its products. The Company does not undertake to update or revise any forward-looking statements, except as, and to the extent required by, applicable securities laws in Canada. See "Cautionary Statement Regarding Forward-Looking Information". Actual results may also be impacted by all of the risk factors in this MD&A and in the Company's annual information form dated March 16, 2020.

DISCLOSURE CONTROLS AND PROCEDURES

Management is responsible for establishing and maintaining a system of disclosure controls and procedures ("DC&P") under National Instrument 52-109 to provide reasonable assurance that all material information relating to the Company and its subsidiaries is gathered and reported to senior management on a timely basis so that appropriate decisions can be made regarding public disclosure.

The Interim Chief Executive Officer and Chief Financial Officer has designed such disclosure controls and procedures, or caused them to be designed under their supervision, to provide reasonable assurance that material information relating to the Company, including its consolidated subsidiaries, is made known to them by others within those entities, particularly during the period in which the disclosures are being prepared to provide reasonable assurance that information required to be disclosed under securities legislation is recorded, processed, summarized and reported within the time periods specified in the securities legislation.

INTERNAL CONTROL OVER FINANCIAL REPORTING

Management is also responsible for establishing and maintaining adequate internal control over financial reporting ("ICFR") to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial reports for external purposes in accordance with IFRS.

The Interim CEO and CFO has designed internal control over financial reporting, or caused it to be designed under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with IFRS as at September 30, 2020.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There have been no material changes in the Company's internal control over financial reporting that occurred during the three and nine months ended September 30, 2020, which have materially affected, or are reasonably likely to affect, the Company's internal controls over financial reporting, other than any duties assumed by the Interim CEO on November 10, 2020.

OUTSTANDING SHARE DATA

As of the date of this MD&A, the Company had the following securities issued and outstanding:

Shares	438,115,672
Warrants	178,730,617
Escrowed share units arising from the HemPoland transaction	1,968,323
Contingent share units arising from the HemPoland transaction	3,047,723
Restricted share units issued to employees	2,122,174
Convertible share units	49,383
Stock options	13,733,730

See the Company's consolidated financial statements for a detailed description of these securities. Each security type is convertible into one common share.